Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Tenofovir disoproxil fumarate (Viread®) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B (CHB) in adults with decompensated liver disease. Treatment should normally be initiated following dialogue with a specialist liver unit. AWMSG is of the opinion that tenofovir disoproxil fumarate (Viread®) is not suitable for shared care within NHS Wales for the above indication |
|||
|
|||
Medicine details |
|||
| Medicine name | tenofovir disoproxil fumarate (Viread®) | ||
| Formulation | 245 mg film-coated tablet | ||
| Reference number | 821 | ||
| Indication | Treatment of chronic hepatitis B in adults with decompensated liver disease |
||
| Company | Gilead Sciences Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 1411 | ||
| NMG meeting date | 08/09/2011 | ||
| AWMSG meeting date | 12/10/2011 | ||
| Ratification by Welsh Government | 01/11/2011 | ||
| Date of issue | 02/11/2011 | ||